Tier 2 — strong

Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin

P J Mulholland, D R Ferry, D Anderson, S A Hussain, A M Young, J E Cook, E Hodgkin, L W Seymour, D J Kerr
Annals of oncology : official journal of the European Society for Medical Oncology 2001 12(2):245

Bibliography

PubMed
PMID 11300332
DOI
10.1023/a:1008372017097
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignEarly clinical pharmacokinetic study with supporting preclinical work
ModelMixed human intervention and laboratory research
Sample6 patients with cancer
InterventionQC12 quercetin prodrug 400 mg orally and intravenously on separate days
DurationOral dosing on day 1; intravenous dosing on day 14
EndpointsExposure and pharmacokinetics

What the study showed, in plain terms

Published in 2001, this source examined forms, absorption and food sources. Design: Early clinical pharmacokinetic study with supporting preclinical work. Sample/model: 6 patients with cancer. The exposure or intervention was QC12 quercetin prodrug 400 mg orally and intravenously on separate days. Follow-up or treatment period: Oral dosing on day 1; intravenous dosing on day 14.

The oral prodrug produced no detectable plasma exposure; intravenous administration released measurable quercetin.

Experimental prodrug and intravenous oncology setting. The findings do not establish cancer efficacy or safe oral supplement dosing.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Forms: Dihydrate, Phytosome, Liposomal and Glycosides. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • The oral prodrug produced no detectable plasma exposure; intravenous administration released measurable quercetin.
  • The recorded outcome domains were Exposure and pharmacokinetics.
  • The result applies to the tested exposure: QC12 quercetin prodrug 400 mg orally and intravenously on separate days; Oral dosing on day 1; intravenous dosing on day 14.

What this study can and cannot tell us

  • Experimental prodrug and intravenous oncology setting. The findings do not establish cancer efficacy or safe oral supplement dosing.
  • A change in blood exposure or a metabolic marker is not a demonstrated improvement in symptoms, disease events or lifespan. The tested formulation and co-administered medicines matter.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Improving quercetin bioavailability: A systematic review and meta-analysis of human intervention studies
Lu Liu et al. · Food chemistry · 2025

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology